Overview

Venetoclax Plus Inotuzumab for B-ALL

Status:
Recruiting
Trial end date:
2026-06-23
Target enrollment:
Participant gender:
Summary
This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: - Venetoclax - Inotuzumab ozogamicin - Dexamethasone
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
AbbVie
Treatments:
Dexamethasone
Inotuzumab Ozogamicin
Venetoclax